A 68-year-old male with a 40-pack-year smoking history presents with chronic dyspnea and cough.
Spirometry reveals a post-bronchodilator FEV1/FVC ratio of 0.65 and an FEV1 of 45% predicted.
He has had three exacerbations in the past year, one requiring hospitalization.
His blood eosinophil count is 350 cells/µL.
According to the 2024 GOLD guidelines, what is the most appropriate initial pharmacologic management?